Characterization of cannabinoid-induced relief of neuropathic pain in rat models of type 1 and type 2 diabetes

Pharmacology Biochemistry and Behavior

Volumn 102, Issue 2, 2012, Pages 335-343

  Vera, Gema ^a   López Miranda, Visitación ^a   Herradón, Esperanza ^a   Martín, María Isabel ^a   Abalo, Raquel ^a  

^a UNIVERSIDAD REY JUAN CARLOS   (Spain)

Author keywords

Cannabinoid; Neuropathic pain; Streptozotocin; Type 1 diabetes; Type 2 diabetes; Zucker Diabetic Fatty rat

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID RECEPTOR AGONIST; PSYCHOTROPIC AGENT; STREPTOZOCIN;

ALLODYNIA; ANALGESIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MECHANICAL STRESS; NEUROPATHIC PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; ZUCKER DIABETIC FATTY RAT;

ANIMALS; BENZOXAZINES; CANNABINOIDS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; MORPHOLINES; NAPHTHALENES; NEURALGIA; RATS; RATS, WISTAR; RATS, ZUCKER;

ANIMALIA; RATTUS; RATTUS NORVEGICUS; RODENTIA;

EID: 84861712806     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2012.05.008     Document Type: Article

References (54)

1. Aring AM, Jones DE, Falko JM. Evaluation and prevention of diabetic neuropathy. Am Fam Physician 2005;71:2123-8.
2. Armstrong RB, Laughlin MH. Metabolic indicators of fibre recruitment in mammalian muscles during locomotion. J Exp Biol 1985;115:201-13.
3. Beltramo M, Bernardini N, Bertorelli R, Campanella M, Nicolussi E, Fredduzzi S, et al. CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur J Neurosci 2006;23:1530-8.
4. Bril V, England J, Franklin GM, Backonja M, Cohen J, Del Toro D et al.; American Academy of Neurology; American Association of Neuromuscular and Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. PM R. 2011;3(4):345-52, 352.e1-21.
5. Brussee V, Guo G, Dong Y, Cheng C, Martinez JA, Smith D, et al. Distal degenerative sensory neuropathy in a long-term type 2 diabetes rat model. Diabetes 2008;57:1664-73.
6. Bujalska M. Effect of cannabinoid receptor agonists on streptozotocin-induced hyperalgesia in diabetic neuropathy. Pharmacology 2008;82:193-200.
7. Clark JB, Palmer CJ, Shaw WN. The diabetic Zucker fatty rat. Proc Soc Exp Biol Med 1983;173(1):68-75.
8. Comelli F, Bettoni I, Colombo A, Fumagalli P, Giagnoni G, Costa B. Rimonabant, a cannabinoid CB1 receptor antagonist, attenuates mechanical allodynia and counteracts oxidative stress and nerve growth factor deficit in diabetic mice. Eur J Pharmacol 2010;637:62-9.
9. Compton DR, Rice KC, De Costa BR, Razdan RK, Melvin LS, Johnson MR, et al. Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther 1993;265:218-26.
10. Doǧrul A, Gül H, Yildiz O, Bilgin F, Güzeldemir ME. Cannabinoids blocks tactile allodynia in diabetic mice without attenuation of its antinociceptive effect. Neurosci Lett 2004;368:82-6.
11. Duby JJ, Campbell RK, Setter SM, White JR, Rasmussen KA. Diabetic neuropathy: an intensive review. Am J Health Syst Pharm 2004;61:160-73.
12. Dyck PJ, Dyck PJ, Larson TS, O'Brien PC, Velosa JA. Patterns of quantitative sensation testing of hypoesthesia and hyperalgesia are predictive of diabetic polyneuropathy: a study of three cohorts. Nerve growth factor study group. Diabetes Care 2000;23:510-7.
13. Einhorn TA, Boskey AL, Gundberg CM, Vigorita VJ, Devlin VJ, Beyer MM. The mineral and mechanical properties of bone in chronic experimental diabetes. J Orthop Res 1988;6:317-23.
14. Ellington HC, Cotter MA, Cameron NE, Ross RA. The effect of cannabinoids on capsaicin-evoked calcitonin gene-related peptide (CGRP) release from the isolated paw skin of diabetic and non-diabetic rats. Neuropharmacology 2002;42:966-75.
15. Fox A, Eastwood C, Gentry C,Manning D, Urban L. Critical evaluation of the streptozotocin model of painful diabetic neuropathy in the rat. Pain 1999;81:307-16.
16. Fox A, Kesingland A, Gentry C, McNair K, Patel S, Urban L, et al. The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 2001;92:91-100.
17. González C, Herradón E, Abalo R, Vera G, Pérez-Nievas BG, Leza JC, et al. Cannabinoid/ agonist WIN 55,212-2 reduces cardiac ischaemia-reperfusion injury in Zucker diabetic fatty rats: role of CB2 receptors and iNOS/eNOS. Diabetes Metab Res Rev 2011;27(4):331-40.
18. Herzberg U, Eliav E, Bennett GJ, Kopin IJ. The analgesic effects of R(C)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist in a rat model of neuropathic pain. Neurosci Lett 1997;221:157-60.
19. IASP TAXONOMY: Updated from: Merskey and N. Bogduk. Pain terms, a current list with definitions and notes on usage. In: Classification of chronic pain, Second Edition, IASP Task Force on Taxonomy. Edited by H., IASP Press, Seattle, 1994. pp 209-214. http://www.iasp-pain.org/AM/Template.cfm?Section=Pain- Definitions.
20. Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP, et al. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci U S A 2003;100:10529-33.
21. Karst M, Wippermann S. Cannabinoids against pain. Efficacy and strategies to reduce psychoactivity: a clinical perspective. Expert Opin Investig Drugs 2009;18:125-33.
22. Li F, Abatan OI, Kim H, Burnett D, Larkin D, Obrosova IG, et al. Taurine reverses neurological and neurovascular deficits in Zucker diabetic fatty rats. Neurobiol Dis 2006;22:669-76.
23. Malcangio M, Tomlinson DR. A pharmacologic analysis of mechanical hyperalgesia in streptozotocin/diabetic rats. Pain 1998;76:151-7.
24. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61-5.
25. Nackley AG, Suplita II RL, Hohmann AG. A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience 2003;117(3):659-70.
26. National Diabetes Statistics. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2011. http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2011.pdf.
27. Ohsawa M, Miyata S, Carlsson A, Kamei J. Preventive effect of acetyl-L-carnitine on the thermal hypoalgesia in streptozotocin-induced diabetic mice. Eur J Pharmacol 2008;588(2-3):213-6.
28. Oltman CL, Coppey LJ, Gellett JS, Davidson EP, Lund DD, Yorek MA. Progression of vascular and neural dysfunction in sciatic nerves of Zucker diabetic fatty and Zucker rats. Am J Physiol Endocrinol Metab 2005;289(1):E113-22.
29. Oltman CL, Davidson EP, Coppey LJ, Kleinschmidt TL, Lund DD, Adebara ET, et al. Vascular and neural dysfunction in Zucker diabetic fatty rats: a difficult condition to reverse. Diabetes Obes Metab 2008;10:64-74.
30. Otto KJ, Wyse BD, Cabot PJ, Smith MT. Longitudinal study of painful diabetic neuropathy in the Zucker diabetic fatty rat model of type 2 diabetes: impaired basal G-protein activity appears to underpin marked morphine hyposensitivity at 6 months. Pain Med 2011;12(3):437-50.
31. Pascual D, Goicoechea C, Suardíaz M, Martín MI. A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats. Pain 2005;118:23-34.
32. Peterson RG, Shaw WN, Neel MA, Little LA, Eichberg J. Zucker diabetic fatty rat as a model for non-insulin-dependent diabetes mellitus. ILAR News 1990;32(3):16-9.
33. Price SR, Bailey JL, Wang X, Jurkovitz C, England BK, Ding X, et al. Muscle wasting in insulinopenic rats results from activation of the ATP-dependent, ubiquitin-proteasome proteolytic pathway by a mechanism including gene transcription. J Clin Invest 1996;98:1703-8.
34. Prisby RD, Swift JM, Bloomfield SA, Hogan HA, Delp MD. Altered bone mass, geometry and mechanical properties during the development and progression of type 2 diabetes in the Zucker diabetic fatty rat. J Endocrinol 2008;199:379-88.
35. Rahn EJ, Makriyannis A, Hohmann AG. Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br J Pharmacol 2007;152:765-77.
36. Richardson JD, Kilo S, Hargreaves KM. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 1998;75:111-9.
37. Romanovsky D, Walker JC, Dobretsov M. Pressure pain precedes development of type 2 disease in Zucker rat model of diabetes. Neurosci Lett 2008;445(3):220-3.
38. Rukwied R, Watkinson A, McGlone F, Dvorak M. Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain 2003;102:283-8.
39. Russo EB. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manage 2008 Feb;4(1):245-59.
40. Shaikh AS, Somani RS. Animal models and biomarkers of neuropathy in diabetic rodents. Indian J Pharmacol 2010;42(3):129-34.
41. Sima AA. The heterogeneity of diabetic neuropathy. Front Biosci 2008;13:4809-16.
42. Smith HS, Argoff CE. Pharmacological treatment of diabetic neuropathic pain. Drugs 2011;71(5):557-89.
43. Suanarunsawat T, Klongpanichapak S, Chaiyabutr N. Role of nitric oxide in renal function in rats with short and prolonged periods of streptozotocin- induced diabetes. Diabetes Obes Metab 1999;1:339-46.
44. Talbot S, Chahmi E, Dias JP, Couture R. Key role for spinal dorsal horn microglial kinin B1 receptor in early diabetic pain neuropathy. J Neuroinflammation 2010 Jun 29;7(1):36.
45. Toth CC, Jedrzejewski NM, Ellis CL, Frey II WH. Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain. Mol Pain 2010;17:6-16.
46. Ulugol A, Karadag HC, Ipci Y, Tamer M, Dokmeci I. The effect of WIN 55,212-2, a cannabinoid agonist, on tactile allodynia in diabetic rats. Neurosci Lett 2004;371:167-70.
47. Vera G, Chiarlone A, Cabezos PA, Pascual D, Martín MI, Abalo R. WIN 55,212-2 prevents mechanical allodynia but not alterations in feeding behaviour induced by chronic cisplatin in the rat. Life Sci 2007;81:468-79.
48. Vinik AI, Suwanwalaikorn S, Stansberry KB, Holland MT, McNitt PM, Colen LE. Quantitative measurement of cutaneous perception in diabetic neuropathy. Muscle Nerve 1995;18:574-84.
49. Vinik A, Ullal J, Parson HK, Casellini CM. Diabetic neuropathies: clinical manifestations and current treatment options. Nat Clin Pract Endocrinol Metab 2006;2:2-13.
50. Williams J, Haller VL, Stevens DL, Welch SP. Decreased basal endogenous opioid levels in diabetic rodents: effects on morphine and delta-9- tetrahydrocannabinoid-induced antinociception. Eur J Pharmacol 2008;584:78-86.
51. Wotherspoon G, Fox A, McIntyre P, Colley S, Bevan S, Winter J. Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience 2005;135:235-45.
52. Zhang F, Hong S, Stone V, Smith PJ. Expression of cannabinoid CB1 receptors in models of diabetic neuropathy. J Pharmacol Exp Ther 2007;323:508-15.
53. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A 1999;96:5780-5.
54. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983;16(2):109-10.